Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analysis from the CLEAR Outcomes study also identified factors like female sex, higher baseline LDL-C, and ezetimibe use that enhance LDL-C reduction in statin-intolerant adults. These findings support bempedoic acid as a safe adjunct or alternative to statins, with ongoing Phase 3 pediatric trials planned. The data reinforce the role of Esperion’s products NEXLETOL and NEXLIZET in managing cholesterol and reducing cardiovascular risk.
Auditoria.AI introduced Governed Autonomy, a new framework allowing AI agents to operate within enterprise-defined policies in finance, reducing the need for human approval on every transaction. This shift addresses governance challenges in AI deploy...
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Microchip Technology has introduced new 3.3 kV HV-D3 mSiC power modules designed to enhance solid-state transformers (SSTs) for AI hyperscale data centers. These modules integrate silicon carbide MOSFETs and Schottky diodes to improve power delivery ...
G. Willi-Food International Ltd. announced a strong first quarter for 2026, with sales increasing by 8.3% to NIS 157 million and gross profit rising 9.7% to NIS 49 million compared to the same period in 2025. Net profit grew by 3% to NIS 20.1 million...
